Christian Lanshoeft
Overview
Explore the profile of Christian Lanshoeft including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
32
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
James A, Lanshoeft C, Steeno G, Spracklin D, You Z, Sharma R, et al.
Drug Metab Dispos
. 2025 Mar;
53(3):100041.
PMID: 40048992
The mixed matrix method (MmM) is a widely used approach by the pharmaceutical industry for early assessment of whether exposures to major human circulating metabolites, of traditional small-molecule drugs, are...
2.
Lanshoeft C, Schutz R, Lozach F, Schlotterbeck G, Walles M
Anal Bioanal Chem
. 2023 Dec;
416(2):559-568.
PMID: 38040943
Ion mobility spectrometry-mass spectrometry (IMS-MS) separates gas phase ions due to differences in drift time from which reproducible and analyte-specific collision cross section (CCS) values can be derived. Internally conducted...
3.
Taft B, Yokokawa F, Kirrane T, Mata A, Huang R, Blaquiere N, et al.
J Med Chem
. 2022 Mar;
65(5):3798-3813.
PMID: 35229610
A series of 5-aryl-2-amino-midazohiaiazole (ITD) derivatives were identified by a phenotype-based high-throughput screening using a blood stage () growth inhibition assay. A lead optimization program focused on improving antiplasmodium potency,...
4.
Pistorius D, Buntin K, Weber E, Richard E, Bouquet C, Wollbrett S, et al.
Chemistry
. 2021 Dec;
28(8):e202103888.
PMID: 34878202
Access to the cyclic depsipeptide FR900359 (FR), a selective G protein inhibitor of high pharmacological interest and a potential lead molecule for targeted therapy of cancers with oncogenic GNAQ or...
5.
Lanshoeft C, Cianferani S, Heudi O
Anal Chem
. 2017 Feb;
89(4):2628-2635.
PMID: 28192936
The quantitative analysis of human immunoglobulin G1 (hIgG1) by mass spectrometry is commonly performed using surrogate peptides after enzymatic digestion. Since some limitations are associated with this approach, a novel...
6.
Lanshoeft C, Wolf T, Walles M, Barteau S, Picard F, Kretz O, et al.
J Pharm Biomed Anal
. 2016 Sep;
131:214-222.
PMID: 27599352
An increasing demand of new analytical methods is associated with the growing number of biotherapeutic programs being prosecuted in the pharmaceutical industry. Whilst immunoassay has been the standard method for...
7.
Walles M, Rudolph B, Wolf T, Bourgailh J, Suetterlin M, Moenius T, et al.
Drug Metab Dispos
. 2016 Apr;
44(7):897-910.
PMID: 27122302
For antibody drug conjugates (ADCs), the fate of the cytotoxic payload in vivo needs to be well understood to mitigate toxicity risks and properly design the first in-patient studies. Therefore,...
8.
Lanshoeft C, Heudi O, Cianferani S, Warren A, Picard F, Kretz O
Bioanalysis
. 2016 Apr;
8(10):1035-49.
PMID: 27095045
Aim: A sensitive generic LC-MS/MS method for hIgG1 quantification in cynomolgus monkey serum using mass spectrometric immunoassay disposable automation research tips (MSIA-D.A.R.T.'S™) is reported. Results: The hIgG1 was captured with...
9.
Lanshoeft C, Stutz G, Elbast W, Wolf T, Walles M, Stoeckli M, et al.
Rapid Commun Mass Spectrom
. 2016 Mar;
30(7):823-32.
PMID: 26969923
Rationale: Antibody-drug conjugates (ADCs) are some of the most promising antibody-related therapeutics. The fate of the cytotoxic moiety of ADCs in vivo after proteolytic degradation of the antibody needs to...
10.
Lanshoeft C, Heudi O, Cianferani S
Anal Biochem
. 2016 Feb;
501:23-5.
PMID: 26893107
The newly developed SMART Digest™ kit was applied for the sample preparation of human immunoglobulin G1 (hIgG1) in rat serum prior to qualitative and quantitative analyses by liquid chromatography tandem...